Scinai Immunotherapeutics Announces In-Vivo Preclinical Study Results Of NanoAb, Says 'NanoAb led to reduced levels of both IL-17 isoforms in the psoriatic skin tissue.'
Portfolio Pulse from Benzinga Newsdesk
Scinai Immunotherapeutics announced positive in-vivo preclinical study results for NanoAb, showing reduced levels of IL-17 isoforms in psoriatic skin tissue.
July 15, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scinai Immunotherapeutics announced that their NanoAb product showed positive preclinical results by reducing IL-17 isoforms in psoriatic skin tissue.
The positive preclinical results for NanoAb could lead to increased investor confidence and potential future revenue from successful product development, likely driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100